Cargando…

The Efficacy and Safety of Low Dose versus Usual Dose of Hyoscine During Endoscopic Retrograde Cholangiopancreatography: A Randomized Clinical Trial

PURPOSE: To evaluate the efficacy and safety of low dose versus usual dose of Hyoscine during endoscopic retrograde cholangiopancreatography (ERCP). PATIENTS AND METHODS: This randomized, open-label clinical trial included 282 patients undergoing ERCP who had duodenal peristalsis interfering with ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Salmanroghani, Hassan, Mirvakili, Massoud, Mirjalili, Mahtabalsadat, Baghbanian, Mahmud, Salmanroghani, Roham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445520/
https://www.ncbi.nlm.nih.gov/pubmed/32903953
http://dx.doi.org/10.2147/CPAA.S263531
_version_ 1783574005908766720
author Salmanroghani, Hassan
Mirvakili, Massoud
Mirjalili, Mahtabalsadat
Baghbanian, Mahmud
Salmanroghani, Roham
author_facet Salmanroghani, Hassan
Mirvakili, Massoud
Mirjalili, Mahtabalsadat
Baghbanian, Mahmud
Salmanroghani, Roham
author_sort Salmanroghani, Hassan
collection PubMed
description PURPOSE: To evaluate the efficacy and safety of low dose versus usual dose of Hyoscine during endoscopic retrograde cholangiopancreatography (ERCP). PATIENTS AND METHODS: This randomized, open-label clinical trial included 282 patients undergoing ERCP who had duodenal peristalsis interfering with cannulation. Patients were randomly divided into two groups: Group one and two received low (5 mg) and usual (10 mg) dose of Hyoscine, respectively. Cardiovascular service consultation was performed for all patients before entering the study and performing ERCP. Hyoscine was injected intravenously, and the spasmolytic effect of the drug was assessed while the papilla was in a completely enface view. The time interval between cessation of peristalsis and its further onset was recorded by the chronometer. Also, patient’s heart rate and blood pressure were monitored during ERCP by digital monitoring. RESULTS: The results showed no statistically significant differences in the mean duration of peristalsis, the duration of the antispasmodic activity and the time required to increase the heart rate between two groups (P=0.38, P=0.48, P=0.32, respectively). No significant differences were observed regarding the average of heart rate and mean arterial blood pressure (MAP) before drug administration between the two groups (P=0.182 and P=0.29, respectively), but after the drug administration, tachycardia and hypotension were significantly higher in the second group (P=0.007 and P=0.001, respectively). There was no statistically significant difference in the frequency of arrhythmia between two groups (P=0.08). The results also showed that tachycardia and hypotension occurred more frequently in men and elderly patients (P <0.05). CONCLUSION: A low dose of Hyoscine is as effective as the usual dose and its side effects such as alteration in blood pressure and heart rate are much fewer, especially in men and elderly patients.
format Online
Article
Text
id pubmed-7445520
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74455202020-09-04 The Efficacy and Safety of Low Dose versus Usual Dose of Hyoscine During Endoscopic Retrograde Cholangiopancreatography: A Randomized Clinical Trial Salmanroghani, Hassan Mirvakili, Massoud Mirjalili, Mahtabalsadat Baghbanian, Mahmud Salmanroghani, Roham Clin Pharmacol Clinical Trial Report PURPOSE: To evaluate the efficacy and safety of low dose versus usual dose of Hyoscine during endoscopic retrograde cholangiopancreatography (ERCP). PATIENTS AND METHODS: This randomized, open-label clinical trial included 282 patients undergoing ERCP who had duodenal peristalsis interfering with cannulation. Patients were randomly divided into two groups: Group one and two received low (5 mg) and usual (10 mg) dose of Hyoscine, respectively. Cardiovascular service consultation was performed for all patients before entering the study and performing ERCP. Hyoscine was injected intravenously, and the spasmolytic effect of the drug was assessed while the papilla was in a completely enface view. The time interval between cessation of peristalsis and its further onset was recorded by the chronometer. Also, patient’s heart rate and blood pressure were monitored during ERCP by digital monitoring. RESULTS: The results showed no statistically significant differences in the mean duration of peristalsis, the duration of the antispasmodic activity and the time required to increase the heart rate between two groups (P=0.38, P=0.48, P=0.32, respectively). No significant differences were observed regarding the average of heart rate and mean arterial blood pressure (MAP) before drug administration between the two groups (P=0.182 and P=0.29, respectively), but after the drug administration, tachycardia and hypotension were significantly higher in the second group (P=0.007 and P=0.001, respectively). There was no statistically significant difference in the frequency of arrhythmia between two groups (P=0.08). The results also showed that tachycardia and hypotension occurred more frequently in men and elderly patients (P <0.05). CONCLUSION: A low dose of Hyoscine is as effective as the usual dose and its side effects such as alteration in blood pressure and heart rate are much fewer, especially in men and elderly patients. Dove 2020-08-20 /pmc/articles/PMC7445520/ /pubmed/32903953 http://dx.doi.org/10.2147/CPAA.S263531 Text en © 2020 Salmanroghani et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Clinical Trial Report
Salmanroghani, Hassan
Mirvakili, Massoud
Mirjalili, Mahtabalsadat
Baghbanian, Mahmud
Salmanroghani, Roham
The Efficacy and Safety of Low Dose versus Usual Dose of Hyoscine During Endoscopic Retrograde Cholangiopancreatography: A Randomized Clinical Trial
title The Efficacy and Safety of Low Dose versus Usual Dose of Hyoscine During Endoscopic Retrograde Cholangiopancreatography: A Randomized Clinical Trial
title_full The Efficacy and Safety of Low Dose versus Usual Dose of Hyoscine During Endoscopic Retrograde Cholangiopancreatography: A Randomized Clinical Trial
title_fullStr The Efficacy and Safety of Low Dose versus Usual Dose of Hyoscine During Endoscopic Retrograde Cholangiopancreatography: A Randomized Clinical Trial
title_full_unstemmed The Efficacy and Safety of Low Dose versus Usual Dose of Hyoscine During Endoscopic Retrograde Cholangiopancreatography: A Randomized Clinical Trial
title_short The Efficacy and Safety of Low Dose versus Usual Dose of Hyoscine During Endoscopic Retrograde Cholangiopancreatography: A Randomized Clinical Trial
title_sort efficacy and safety of low dose versus usual dose of hyoscine during endoscopic retrograde cholangiopancreatography: a randomized clinical trial
topic Clinical Trial Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445520/
https://www.ncbi.nlm.nih.gov/pubmed/32903953
http://dx.doi.org/10.2147/CPAA.S263531
work_keys_str_mv AT salmanroghanihassan theefficacyandsafetyoflowdoseversususualdoseofhyoscineduringendoscopicretrogradecholangiopancreatographyarandomizedclinicaltrial
AT mirvakilimassoud theefficacyandsafetyoflowdoseversususualdoseofhyoscineduringendoscopicretrogradecholangiopancreatographyarandomizedclinicaltrial
AT mirjalilimahtabalsadat theefficacyandsafetyoflowdoseversususualdoseofhyoscineduringendoscopicretrogradecholangiopancreatographyarandomizedclinicaltrial
AT baghbanianmahmud theefficacyandsafetyoflowdoseversususualdoseofhyoscineduringendoscopicretrogradecholangiopancreatographyarandomizedclinicaltrial
AT salmanroghaniroham theefficacyandsafetyoflowdoseversususualdoseofhyoscineduringendoscopicretrogradecholangiopancreatographyarandomizedclinicaltrial
AT salmanroghanihassan efficacyandsafetyoflowdoseversususualdoseofhyoscineduringendoscopicretrogradecholangiopancreatographyarandomizedclinicaltrial
AT mirvakilimassoud efficacyandsafetyoflowdoseversususualdoseofhyoscineduringendoscopicretrogradecholangiopancreatographyarandomizedclinicaltrial
AT mirjalilimahtabalsadat efficacyandsafetyoflowdoseversususualdoseofhyoscineduringendoscopicretrogradecholangiopancreatographyarandomizedclinicaltrial
AT baghbanianmahmud efficacyandsafetyoflowdoseversususualdoseofhyoscineduringendoscopicretrogradecholangiopancreatographyarandomizedclinicaltrial
AT salmanroghaniroham efficacyandsafetyoflowdoseversususualdoseofhyoscineduringendoscopicretrogradecholangiopancreatographyarandomizedclinicaltrial